Publications by authors named "Adalgisa Condoluci"

Claim this Profile
A
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.
Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk, Adalgisa Condoluci

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, Katia Pini, Georg Stüssi

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment.
Vanessa Cristaldi, Lodovico Terzi di Bergamo, Lucrezia Patruno, Marinos Kallikourdis, Giada Andrea Cassanmagnago, Adalgisa Condoluci

Front Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.
Max J Rieger, Thomas Pabst, Barbara Jeker, Pamella Paul, Fabio Bergamini, Adalgisa Condoluci

Ann Hematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.
Riccardo Bomben, Antonella Zucchetto, Roberta Laureana, Annalisa Chiarenza, Jacopo Olivieri, Adalgisa Condoluci

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis.
Francesco Marchi, Chiara Kessler, Daniela Distefano, Lodovico Terzi di Bergamo, Luca Fumagalli, Adalgisa Condoluci

Amyloid· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation.
Ilaria Romano, Adalgisa Condoluci, Davide Rossi

Clin Lymphoma Myeloma Leuk· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Adalgisa Condoluci

Am J Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Special issue on circulating tumor DNA: Introductory editorial.
Adalgisa Condoluci, Davide Rossi

Semin Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, Anna Maria Frustaci, Riccardo Moia, Adalgisa Condoluci

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.
Adalgisa Condoluci, Lisa Milan, Gabriela Forestieri, Lodovico Terzi di Bergamo, Valeria Spina

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of resistance to venetoclax.
Adalgisa Condoluci, Davide Rossi

Blood· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biology and Treatment of Richter Transformation.
Adalgisa Condoluci, Davide Rossi

Front Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Adalgisa Condoluci

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, Brendan Hodkinson, Gabriela Forestieri, Adalgisa Condoluci

Blood Adv· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of transthyretin amyloidosis.
Adalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, Aju P Pazhenkottil, Paolo Arosio

Swiss Med Wkly· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination.
Micol G Cittone, Raphael Battegay, Adalgisa Condoluci, Lodovico Terzi di Bergamo, Eliana Fernandes

J Thromb Haemost· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Adalgisa Condoluci

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Adalgisa Condoluci

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
Fortunato Morabito, Giovanni Tripepi, Riccardo Moia, Anna Grazia Recchia, Paola Boggione, Adalgisa Condoluci

Front Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Adalgisa Condoluci

Am J Hematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation.
Adalgisa Condoluci, Lorenzo Alberio, Francisco-Javier Gomez, Jan-Dirk Studt, Christelle Orlando

Thromb Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Richter Syndrome.
Adalgisa Condoluci, Davide Rossi

Curr Oncol Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis